Blood Thinning Drug Expected To Make Profit Despite Xarelto Lawsuit Filings

March 31, 2016 – – BloodThinnerHelp.com reports on FiercePharma.com projected sales for Xarelto into 2018. According to analysts, the drug is projected to make an estimated $3.68 billion in sales despite the growing number of lawsuits against the manufacturers claiming that use of the drug resulted in adverse side effects.

In 2011, the Food & Drug Administration approved Xarelto (rivaroxaban), manufactured by Johnson & Johnson and Bayer AG, for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. In 2013, the manufacturers of Xarelto profited with sales of $1.4 billion and in January 2014, the first lawsuit alleging Xarelto was the cause of a patient’s death because of uncontrollable bleeding was filed. Since then, thousands more lawsuits have been filed, resulting in a mass tort program in Philadelphia that has now reached 620 cases as well as the creation of a Multidistrict Litigation panel in Eastern Louisiana that is currently up to 2,800 cases. Most lawsuits allege that Xarelto caused uncontrollable internal bleeding resulting in death or serious injury.

One of the most common side effects patients using Xarelto have reported is internal bleeding. Physicians usually check for internal bleeding by first completing a thorough history of the patient and may do blood tests or imaging tests to look for the bleeding source. The possibility of gastrointestinal bleeding may be checked by a fiber optic scope that looks into the esophagus and stomach. Other common reported injuries that patients have associated with Xarelto are brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke and heart attacks.

As plaintiffs await their day in court, Attorney Joseph Osborne is working to help ensure that everyone affected negatively by the drug will have the opportunity to explore their legal options. These individuals may be entitled to legal action and significant compensation. Currently, Osborne is offering free legal consultations for qualifying individuals.

For more information or to ask questions about Xarelto, contact Joseph Osborne Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009000